Melatonin as a candidate compound for neuroprotection in amyotrophic lateral 
sclerosis (ALS): high tolerability of daily oral melatonin administration in 
ALS patients

Jacob, S.; Poeggeler, B.; Weishaupt, J. H.; Siren, Anna-Leena; Hardeland, R.; Bahr, M.; Ehrenreich, Hannelore

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients

MPS-Authors

/persons/resource/persons182411

Siren, Anna-Leena
Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182138

Ehrenreich, Hannelore
Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Jacob, S., Poeggeler, B., Weishaupt, J. H., Siren, A.-L., Hardeland, R., Bahr, M., & Ehrenreich, H. (2002). Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. Journal of Pineal Research, 33(3), 186-187.

引用: https://hdl.handle.net/11858/00-001M-0000-0029-191C-B

要旨

要旨はありません